Bristol Myers Squibb Exceeds Quarterly Projections, Adjusts Forecast Amid Tariff Concerns

The pharmaceutical powerhouse reported better-than-expected performance for the first quarter on Thursday, and consequently adjusted its revenue and profit outlook upward, focusing on reducing operational expenses.

The company anticipates its 2025 revenues to range between $45.8 billion and $46.8 billion, slightly adjusted from an earlier approximation of $45.5 billion. Furthermore, the projected adjusted earnings per share for the full year have been revised to between $6.70 and $7, compared against the previous forecast of $6.55 to $6.85.

Tariff Revisions and Impact

Significantly, new projections incorporate the speculated influence of existing tariffs on American goods sent to China yet omit any considerations for President Trump's proposed pharmaceutical tariffs targeting the U.S. market.

China’s Strategic Importance

Recognizing the importance of China as a market, Bristol Myers Squibb has launched its 'China 2030 Strategy.' This initiative aims to expand the availability of its treatments to tackle unmet health needs such as gastric cancer and incorporates Chinese participants into more clinical studies.

The improved outlook can be attributed to solid performance in its newer drug lineup, combined with unexpectedly strong sales from legacy medications.

Cost-Cutting Measures and Growth Strategies

Anticipating substantial savings, Bristol Myers aims to cut $2 billion in operational spending by 2027, in addition to $1.5 billion targeted by year’s end.

Further complications arose post-approval of its schizophrenia medication, Cobenfy, prompting analysts to readjust sales estimates downward.

Despite these challenges, Cobenfy and other growth-oriented medications are seen as countermeasures to the anticipated decline in income from flagship drugs reaching patent expiry, such as the notable blood thinner, Eliquis, and the cancer immunotherapy, Opdivo.

First Quarter Financial Performance

In the latest financial quarter, Bristol Myers reported a net income of $2.5 billion or $1.20 per share, as compared to a $11.9 billion loss or $5.89 per share deficit in the same quarter last year. Excluding certain irregular items, adjusted earnings stood at $1.80 per share.

Revenue saw a 6% decline to $11.2 billion relative to the equivalent timeframe last year.

Drug-specific Sales Insights

Sales for Eliquis dropped 4% to $3.57 billion but surpassed analysts’ $3.34 billion predictions. However, the drug's exclusivity is expected to conclude by 2028, with potential price reductions in 2026 under new Medicare agreements according to the Inflation Reduction Act.

In contrast, Pomalyst generated $658 million, reflecting a 24% decrease, while Revlimid secured $936 million, a staggering 44% drop year-over-year.

Meanwhile, revenue from its growth portfolio was robust, jumping 16% to $5.56 billion. Opdivo, maintaining an upward trajectory, achieved $2.27 billion, overshadowing analyst estimates.

Cobenfy, still in the early stages, recorded $27 million in sales for the quarter.